The Tumor Suppressor p53 and the Oncoprotein Simian Virus 40 T Antigen Bind to Overlapping Domains on the MDM2 Protein

REFERENCES

• Baker, S. J., E. R. Fearon, J. M. Nigro, S. R. Hamilton, A. C. Preisinger, J. M. Jessup, P. Van Tuizen, D. H. Ledbetter, D. F. Barker, Y. Nakamura, R. White, and B. Vogelstein. 1989. Chromosome 17 deletions and p53 gene mutations in colorectal carcinoma. Science 244:217–221.
   PubMed Web of Science ®Google Scholar
• Baker, S. J., K. Markowitz, E. R. Fearon, J. K. V. Willson, and B. Vogelstein. 1990. Suppression of human colorectal carcinoma cell growth by wild-type p53. Science 249:912–915.
   PubMed Web of Science ®Google Scholar
• Barak, Y., T. Juven, R. Haffaer, and M. Oren. 1993. MDM2 expression is induced by wild type p53 activity. EMBO J. 12:461–468.
   PubMed Web of Science ®Google Scholar
• Chen, J., V. Marechal, and A. J. Levine. 1993. Mapping of the p53 and mdm-2 interaction domains. Mol. Cell. Biol. 13:4107–4114.
   PubMed Web of Science ®Google Scholar
• Crook, T., J. A. Tidy, and K. H. Vousden. 1991. Degradation of p53 can be targeted by HPV E6 sequences distinct from those required for p53 binding and transactivation. Cell 67:547–556.
   PubMed Web of Science ®Google Scholar
• Deb, S., C. T. Jackson, M. A. Subler, and D. W. Martin. 1992. Modulation of cellular and viral promoters by mutant human p53 proteins found in tumor cells. J. Virol. 66:6164–6170.
   PubMed Web of Science ®Google Scholar
• Deb, S. P.%% Unpublished data.
   Google Scholar
• Deb, S. P., and P. Tegtmeyer. 1987. ATP enhances the binding of simian virus 40 large T antigen to the origin of replication. J. Virol. 61:3649–3654.
   PubMedGoogle Scholar
• Diller, L., J. Kassel, C. E. Nelson, M. A. Gryka, G. Litwak, M. Gebhardt, B. Bressac, M. Ozturk, S. J. Baker, B. Vogelstein, and S. H. Friend. 1990. p53 functions as a cell cycle control protein in osteosarcomas. Mol. Cell. Biol. 10:5772–5781.
   PubMed Web of Science ®Google Scholar
• Fakharzadeh, S., R. S. Trusko, and D. L. George. 1991. Tumorigenic potential associated with enhanced expression of a gene that is amplified in a mouse tumor cell line. EMBO J. 10:1565–1569.
   PubMed Web of Science ®Google Scholar
• Eliyahu, D., D. Michalovitz, S. Eliyahu, O. Pinhasi-Kimbi, and M. Oren. 1989. Wild-type p53 can inhibit oncogene-mediated focus formation. Proc. Natl. Acad. Sci. USA 86:8763–8767.
   PubMed Web of Science ®Google Scholar
• Eliyahu, D., A. Raz, P. Gruss, D. Givol, and M. Oren. 1984. Participation of p53 cellular tumour antigen in transformation of normal embryonic cells. Nature (London) 312:646–649.
   PubMed Web of Science ®Google Scholar
• Fanning, E., and R. Knippers. 1992. Structure and function of simian virus 40 large tumor antigen. Annu. Rev. Biochem. 61:55–85.
   PubMed Web of Science ®Google Scholar
• Farmer, G., J. Bargonetti, H. Jho, P. Friedman, R. Prywes, and C. Prives. 1992. Wild-type p53 activates transcription in vitro. Nature (London) 358:83–86.
   PubMed Web of Science ®Google Scholar
• Fields, S., and S. L. Jang. 1990. Presence of a potent transcription activating sequence in the p53 protein. Science 249:1046–1049.
   PubMed Web of Science ®Google Scholar
• Finlay, C. A. 1993. The mdm-2 oncogene can overcome wildtype p53 suppression of transformed cell growth. Mol. Cell. Biol. 13:301–306.
   PubMed Web of Science ®Google Scholar
• Finlay, C. A., P. W. Hinds, T. H. Tan, D. Eliyahu, M. Oren, and A. J. Levine. 1988. Activating mutations for transformation by p53 produce a gene product that forms an hsc-p53 complex with an altered half life. Mol. Cell. Biol. 8:531–539.
   PubMed Web of Science ®Google Scholar
• Funk, W. D., D. T. Pak, R. H. Karas, W. E. Wright, and J. W. Shay. 1992. A transcriptionally active DNA-binding site for human p53 protein complexes. Mol. Cell. Biol. 12:2866–2871.
   PubMed Web of Science ®Google Scholar
• Gorman, C. M., L. F. Moffat, and B. H. Howard. 1982. Recombinant genomes which express chloramphenicol acetyltransferase in mammalian cells. Mol. Cell. Biol. 2:1044–1051.
   PubMed Web of Science ®Google Scholar
• Graham, F. L., and A. J. van der Eb. 1973. A new technique for the assay of infectivity of human adenovirus 5 DNA. Virology 52:456–467.
   PubMed Web of Science ®Google Scholar
• Hinds, P. W., C. A. Finlay, R. S. Quartin, S. J. Baker, E. R. Fearon, B. Vogelstein, and A. J. Levine. 1990. Mutant p53 cDNAs from human colorectal carcinomas can cooperate with ras in transformation of primary rat cells. Cell Growth Differ. 1:571–580.
   PubMedGoogle Scholar
• Hollstein, M., D. Sidransky, B. Vogelstein, and C. C. Harris. 1991. p53 mutations in human cancers. Science 253:49–53.
   PubMed Web of Science ®Google Scholar
• Iggo, R., K. Gatter, J. Bartek, D. Lane, and A. L. Harris. 1990. Increased expression of mutant forms of p53 oncogene in primary lung cancer. Lancet 335:675–679.
   PubMed Web of Science ®Google Scholar
• Innis, M. A., D. H. Gelfand, J. J. Sninsky, and T. J. White (ed.). 1990. PCR protocols. A guide to methods and applications. Academic Press, Inc., San Diego, Calif.
   Google Scholar
• Jenkins, J. R., K. Rudge, P. Chumakov, and G. A. Curie. 1985. The cellular oncogene p53 can be activated by mutagenesis. Nature (London) 317:816–817.
   PubMedGoogle Scholar
• Kern, S. E., J. A. Pietenpol, S. Thiagalingam, A. Seymour, K. W. Kinzler, and B. Vogelstein. 1992. Oncogenic forms of p53 inhibit p53-regulated gene expression. Science 256:827–830.
   PubMed Web of Science ®Google Scholar
• Ladanyi, M., C. Cha, R. Lewis, S. C. Jhanwar, A. G. Huvos, and J. H. Healey. 1993. MDM2 gene amplification in metastic osteosarcoma. Cancer Res. 53:16–18.
   PubMed Web of Science ®Google Scholar
• Lai, J.-S., and W. Herr. 1992. Ethidium bromide provides a simple tool for identifying genuine DNA-independent protein associations. Proc. Natl. Acad. Sci. USA 89:6958–6962.
   PubMed Web of Science ®Google Scholar
• Landschulz, W. H., P. F. Johnson, and S. McKnight. 1989. The DNA binding domain of the rat liver nuclear protein C/EBP is bipartite. Nature (London) 243:1681–1688.
   Google Scholar
• Lane, D. P., and L. W. Crawford. 1979. T antigen is bound to a host protein in SV40-transformed cells. Nature (London) 278:216–263.
   Google Scholar
• Lanford, R. E. 1988. Expression of simian virus T antigen in insect cells using a baculovirus expression vector. Virology 167:72–81.
   PubMedGoogle Scholar
• Lechner, M. S., D. H. Mach, A. B. Fincle, T. Crook, K. H. Vousden, and L. A. Laiminis. 1992. Human papillomavirus E6 proteins bind p53 in vivo and abrogate p53-mediated repression of transcription. EMBO J. 11:3045–3052.
   PubMed Web of Science ®Google Scholar
• Lee, W. S., C. Cheng-Kao, G. O. Bryant, X. Liu, and A. J. Berl 1991. Adenovirus ElA binds the TATA-box transcription factor TFIID. Cell 67:365–376.
   PubMedGoogle Scholar
• Levine, A. J., J. Momand, and C. A. Finlay. 1991. The p53 tumor suppressor gene. Nature (London) 351:453–456.
   PubMed Web of Science ®Google Scholar
• Linzer, D. I. H., and A. J. Levine. 1979. Characterization of a 54K dalton cellular SV40 tumor antigen present in SV40-transformed cells and uninfected embryonal carcinoma cells. Cell 17:43–52.
   PubMed Web of Science ®Google Scholar
• Martin, D. W., R. M. Mufioz, M. A. Subler, and S. Deb. 1993. p53 Binds to the TATA-binding protein-TATA complex. J. Biol. Chem. 268:13062–13067.
   PubMedGoogle Scholar
• Masuda, J., C. Miller, H. P. Koeffer, H. Battifora, and M. J. Cline. 1987. Rearrangement of the p53 gene in human osteogenic sarcomas. Proc. Natl. Acad. Sci. USA 84:7716–7719.
   PubMed Web of Science ®Google Scholar
• Michalivitz, D., O. Halevy, and M. Oren. 1990. Conditional inhibition of transformation and of cell proliferation by a temperature-sensitive mutant of p53. Cell 62:671–680.
   PubMedGoogle Scholar
• Mietz, J. A., T. Unger, J. M. Huibregtse, and P. M. Howley. 1992. The transcriptional transactivation function of wild-type p53 is inhibited by SV40 large T antigen and by HPV-16 E6 oncoprotein. EMBO J. 11:5013–5020.
   PubMed Web of Science ®Google Scholar
• Momand, J., G. P. Zambetti, D. C. Olson, D. George, and A. J. Levine. 1992. The mdm-2 oncogene product forms a complex with the p53 protein and inhibits p53-mediated transactivation. Cell 69:1237–1245.
   PubMed Web of Science ®Google Scholar
• Nigro, J. M., S. J. Baker, A. C. Preisinger, J. M. Jessup, R. Hostetter, K. Clearly, S. H. Bigner, N. Davidson, S. Baylin, P. Devillee, T. Glover, F. S. Collins, A. Weston, R. Modali, C. C. Harris, and B. Vogelstein. 1989. Mutations in the p53 gene occur in diverse human tumor types. Nature (London) 342:705–708.
   PubMed Web of Science ®Google Scholar
• Oliner, J. D., K. W. Kinzler, P. S. Meltzer, D. L. George, and B. Vogelstein. 1992. Amplification of a gene encoding a p53-associated protein in human sarcomas. Nature (London) 358:80–83.
   PubMed Web of Science ®Google Scholar
• Oliner, J. D., J. A. Pietenpol, S. Thiagalingam, J. Gyuris, R. W. Kinzler, and B. Vogelstein. 1993. Oncoprotein MDM2 conceals the activation domain of tumor suppressor p53. Nature (London) 362:857–860.
   PubMed Web of Science ®Google Scholar
• Parada, L. F., H. Land, R. A. Wienberg, D. Wolf, and V. Rotter. 1984. Cooperation between gene encoding p53 tumor antigen and ras in cellular transformation. Nature (London) 312:649–651.
   PubMed Web of Science ®Google Scholar
• Ptashne, M.%% 1988. How eukaryotic transcriptional activators work. Nature (London) 335:15–719.
   Google Scholar
• Raycroft, L., W. Hongyun, and G. Lozano. 1990. Transcriptional activation by wild-type but not transforming mutants of the p53 anti-oncogene. Science 249:1049–1051.
   PubMed Web of Science ®Google Scholar
• Sambrook, J., E. F. Fritsch, and T. Maniatis. 1989. Molecular cloning: a laboratory manual, 2nd ed. Cold Spring Harbor Laboratory, Cold Spring Harbor, N.Y.
   Google Scholar
• Sarnow, P., Y. S. Ho, J. Williams, and A. J. Levine. 1982. Adenovirus Elb-58kd tumor antigen and SV40 large tumor antigen are physically associated with the same 54kd cellular protein in transformed cells. Cell 28:387–394.
   PubMed Web of Science ®Google Scholar
• Scheffner, M., B. A. Werness, J. M. Huibregtse, A. J. Levine, and P. M. Howley. 1990. The E6 oncoprotein encoded by human papillomavirus types 16 and 18 promotes the degradation of p53. Cell 63:1192–1136.
   Google Scholar
• Sekimizi, K., D. Bramhill, and A. Kornberg. 1987. ATP activates dnaA protein in initiating replication of plasmids bearing the origin of the E. coli chromosome. Cell 50:259–265.
   PubMedGoogle Scholar
• Shay, J. W., H. Werbin, W. D. Funk, and W. E. Wright. 1992. Cellular and molecular advances in elucidating p53 function. Mutat. Res. 277:163–171.
   PubMed Web of Science ®Google Scholar
• Stürzbecher, H.-W., R. Brain, C. Addison, K. Rudge, M. Remm, M. Grimaldi, E. Keenan, and J. R. Jenkins. 1992. A C-terminal α-helix plus basic region motif is the major structural determinant of p53 tetrameritation. Oncogene 7:1513–1523.
   PubMedGoogle Scholar
• Subler, M. A., D. W. Martin, and S. Deb. 1992. Inhibition of viral and cellular promoters by human wild-type p53. J. Virol. 66:4757–4762.
   PubMedGoogle Scholar
• Takahashi, T., M. M. Nau, I. Chiba, M. J. Birrer, R. K. Rosenberg, M. Vinocour, M. Levitt, H. Pass, A. F. Gazdar, and J. D. Minna. 1989. p53: a frequent target for genetic abnormalities in lung cancer. Science 246:491–494.
   PubMed Web of Science ®Google Scholar
• Thomas, R., L. Kaplan, N. Reich, D. P. Lane, and A. J. Levine. 1983. Characterization of human p53 antigen employing primate specific monoclonal antibodies. Virology 131:502–517.
   PubMedGoogle Scholar
• Turner, R., and R. Tjian. 1989. Leucine repeats and an adjacent DNA binding domain mediate the formation of functional cFoscJun heterodimers. Nature (London) 243:1689–1694.
   Google Scholar
• Unger, T., M. M. Nau, S. Segal, and J. D. Minna. 1992. p53: a transdominant regulator of transcription whose function is ablated by mutations occurring in human cancer. EMBO J. 11:1383–1390.
   PubMed Web of Science ®Google Scholar
• Vogelstein, B.%% 1990. Cancer: a deadly inheritance. Nature (London) 348:681–682.
   PubMed Web of Science ®Google Scholar
• Wang, E. H., P. N. Friedman, and C. Prives. 1989. The murine p53 protein blocks replication of SV40 DNA in vitro by inhibiting the initiation functions of SV40 large T antigen. Cell 57:379–392.
   PubMed Web of Science ®Google Scholar
• Weintraub, H., S. Hauschka, and S. J. Tapscott. 1991. The MCK enhancer contains a p53 responsive element. Proc. Natl. Acad. Sci. USA 88:4570–4571.
   PubMed Web of Science ®Google Scholar
• Werness, B. A., A. J. Levine, and P. M. Howley. 1990. Association of human papillomavirus types 16 and 18 E6 proteins with p53. Science 248:76–79.
   PubMed Web of Science ®Google Scholar
• Zambetti, G. P., J. Bargonetti, K. Walker, C. Prives, and A. J. Levine. 1992. Wild-type p53 mediates positive regulation ofgene expression through a specific DNA sequence element. Genes Dev. 6:1143–1152.
   PubMed Web of Science ®Google Scholar